Microbiological Characterization and Antibiotic Resistance Profiling of Providencia Spp,: An Emerging Pathogen Isolated From Urinary Tract Infections

NCT07204769 | Not Yet Recruiting

• 1 other identifier: Providencia UTI
• Study Type: observational
• Target: 241
• Locations: 1 country
• Sites: 1

Brief Summary

Aims of the Research:

1. 1.Isolation and identification of Providencia spp. from UTIs.
2. 2.Genotypic confirmation of Providencia isolates.
3. 3.Determination of antimicrobial sensitivity patterns of isolated Providencia spp.
4. 4.Characterization of some virulence factors of Providencia spp.
5. 5.Molecular characterization of multidrug-resistance gene antibiotics.
6. 6.Determination of risk factors for Providencia UTIs.

Conditions

Urinary Tract Infection

Outcome Measures

Primary Outcomes (1)

• Determination of prevalence of Providencia species refers specifically to urinary tract infection patients with gram-negative bacterial isolates.

  Through study completion, an average of 1 year

Interventions

Antibiotic sensitivity DRUG

Molecular characterization of multidrug-resistance gene antibiotics.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with UTI diagnosed through clinical examination and urine analysis.

You may qualify if:

• Patients with UTI diagnosed through clinical examination and urine analysis. Informed consent will be obtained from each patient before Participation in the study.

You may not qualify if:

• Patients currently on antibiotics.
• Patients with any anatomical abnormalities in the urinary tract C) Patients having UTI by gram +ve organisms.

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Assiut University

Asyut, Egypt

Location

Related Publications (9)

• Çetin ET, et al. Providencia spp. in nosocomial urinary infections. Turk J Med Sci. 1998;28(1):59-62

  BACKGROUND

• Ewing WH. The tribe Proteeae: its nomenclature and taxonomy. Int J Syst Evol Microbiol. 1962;12(3):93-102

  BACKGROUND

• Charbek EPN. Providencia infections treatment & management: medical care, surgical care, consultations. Medscape. 2019

  BACKGROUND

• Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110. doi: 10.1592/phco.26.8.1099.

  PMID: 16863487 BACKGROUND

• Guidone GHM, Cardozo JG, Silva LC, Sanches MS, Galhardi LCF, Kobayashi RKT, Vespero EC, Rocha SPD. Epidemiology and characterization of Providencia stuartii isolated from hospitalized patients in southern Brazil: a possible emerging pathogen. Access Microbiol. 2023 Oct 18;5(10):000652.v4. doi: 10.1099/acmi.0.000652.v4. eCollection 2023.

  PMID: 37970084 BACKGROUND

• Kurmasheva N, Vorobiev V, Sharipova M, Efremova T, Mardanova A. The Potential Virulence Factors of Providencia stuartii: Motility, Adherence, and Invasion. Biomed Res Int. 2018 Feb 21;2018:3589135. doi: 10.1155/2018/3589135. eCollection 2018.

  PMID: 29682537 BACKGROUND

• Dong X, Xiang Y, Yang P, Wang S, Yan W, Yuan Y, Zhou S, Zhou K, Liu J, Zhang Y. Novel Providencia xianensis sp. nov.: A multidrug-resistant species identified in clinical infections. Eur J Clin Microbiol Infect Dis. 2024 Jul;43(7):1461-1467. doi: 10.1007/s10096-024-04821-y. Epub 2024 May 7.

  PMID: 38714595 BACKGROUND

• O'Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev. 2000 Oct;13(4):534-46. doi: 10.1128/CMR.13.4.534.

  PMID: 11023955 BACKGROUND

• Wie SH. Clinical significance of Providencia bacteremia or bacteriuria. Korean J Intern Med. 2015 Mar;30(2):167-9. doi: 10.3904/kjim.2015.30.2.167. Epub 2015 Feb 27. No abstract available.

  PMID: 25750557 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Urine samples

MeSH Terms

Conditions

Urinary Tract Infections

Interventions

Drug Collateral Sensitivity

Condition Hierarchy (Ancestors)

Infections; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Drug Interactions; Pharmacological Phenomena; Pharmacological and Toxicological Phenomena; Physiological Phenomena

Study Officials

• Aya Tareq Diab, Bachelor's degree

  Assiut University

  PRINCIPAL INVESTIGATOR

• Prof: Mona Hussein Abdel-Rahim, PhD

  Assiut University

  STUDY DIRECTOR

• Dr. Rawhia Fathy Abdel Hamid, Doctorate

  Assiut University

  STUDY CHAIR

Central Study Contacts

Aya Tareq Diab, Bachelor's degree

CONTACT

+201157456012; ay39090ta@gmail.com

Rawhia Fathy Abdel-Hamid, Doctorate

CONTACT

01110965594; rawhiafathy@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Teaching assistant at Medical microbiology and Immunology department

Study Record Dates

• First Submitted: September 22, 2025
• First Posted: October 2, 2025
• Study Start: May 1, 2026
• Primary Completion (Estimated): August 1, 2027
• Study Completion (Estimated): September 1, 2027
• Last Updated: October 2, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)